SB 1076 Arizona Senate · 57th Legislature - First Regular Session

newborn screening; Duchenne muscular dystrophy

SB 1076 adds Duchenne muscular dystrophy (a severe muscle-wasting condition) to Arizona's mandatory newborn screening program. It requires all newborns (under 28 days old) and infants (29 days to 2 years) in Arizona to be screened for this condition as part of the state's existing newborn screening system. The bill mandates that Arizona's screening panel aligns with the federal recommended uniform screening panel, adding DMD to the list within two years of its federal inclusion. The effective date is either October 1, 2027, or two years after the federal panel adopts DMD, whichever comes first. This change expands screening coverage to detect DMD early, enabling timely medical intervention.
Bill status passed 3 of 5 stages cleared
Introduction
Jan 2025
Committee Review
Mar 2025
Senate Passage
Feb 2025
House Passage
Governor
Introduced Jan 16, 2025 Last action Mar 12, 2025
Maddy AI version diff · 1 comparison

What changed between versions

Introduced Version Senate Engrossed Version · 3 edits · Feb 12, 2025
MINOR
This bill amends Arizona's newborn screening laws to formally add Duchenne muscular dystrophy to the state's screening panel. The changes primarily involve formatting and structural updates to the bill text, with one substantive addition requiring the department of health services to include Duchenne muscular dystrophy in newborn screening tests. The effective date remains tied to either October 1, 2027, or two years after the federal government adds this condition to its recommended screening panel, whichever comes first.
Scope change
The bill's scope is expanded to include Duchenne muscular dystrophy as a condition screened for in newborns, aligning Arizona with federal recommendations.
REQUIREMENT

Added requirement for the department of health services to include Duchenne muscular dystrophy in the state's newborn screening panel in addition to existing conditions.

TIMELINE

Effective date remains contingent on either October 1, 2027, or two years after federal inclusion of Duchenne muscular dystrophy in the recommended uniform screening panel.

TECHNICAL

Significant formatting and structural changes to the bill text, including reorganization of subsections and addition of proper bill headers and formatting markers.

Floor votes · Senate Feb 12, 2025

How they voted

253
Passed · 2 other
Total votes 30
Feb 12, 2025
D Democratic13
11 Yea 2
84% Yea
R Republican17
14 Yea 3 Nay
82% Yea
Vote distribution
All Yea All Nay Mixed No data
Full legislative history

Actions timeline

Total actions
10
Key actions
5
Committee
3
Amendments
1
Mar 12, 2025
Lower · Passed
DPA
lower
Mar 3, 2025
Lower · Passed
DP
lower
Feb 12, 2025
Upper · Passed
PASSED
upper
Jan 28, 2025
Upper · Passed
DP
upper
Jan 22, 2025
Upper · Passed
DP
upper
1 primary · 4 co-sponsors

Sponsors